Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Significant Growth in Short Interest

Posted by Amy Steele on Jan 13th, 2025

Vincerx Pharma, Inc. (NASDAQ:VINC – Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 4,710,000 shares, an increase of 1,022.5% from the December 15th total of 419,600 shares. Based on an average daily volume of 6,840,000 shares, the short-interest ratio is presently 0.7 days.

Analysts Set New Price Targets

Separately, Leerink Partners lowered their target price on Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Read Our Latest Stock Report on VINC

Vincerx Pharma Price Performance

Shares of NASDAQ:VINC traded down $0.01 during trading on Monday, hitting $0.18. 1,958,831 shares of the company’s stock were exchanged, compared to its average volume of 4,464,351. The business’s 50-day simple moving average is $0.25 and its 200 day simple moving average is $0.49. The company has a market cap of $6.02 million, a price-to-earnings ratio of -0.17 and a beta of 1.48. Vincerx Pharma has a 52-week low of $0.18 and a 52-week high of $9.37.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP grew its position in shares of Vincerx Pharma, Inc. (NASDAQ:VINC – Free Report) by 359.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 328,533 shares of the company’s stock after acquiring an additional 256,967 shares during the quarter. Marshall Wace LLP owned about 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent reporting period. 44.02% of the stock is currently owned by hedge funds and other institutional investors.

About Vincerx Pharma

(Get Free Report)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.